Please login to the form below

Not currently logged in
Email:
Password:

Covance and Sihuan Pharma partner on portfolio development

Will collaborate on preclinical and clinical stages

Covance 

LabCorp's Covance and Shandon XuanZhu, a subsidiary of Chinese R&D firm Sihuan Pharmaceutical, have announced a partnership on preclinical and clinical portfolio development.

As part of the alliance, Covance will support the global development of Sihuan Pharmaceutical's drug candidate pipeline, which consists of multiple compounds that address unmet needs across therapeutics areas including cardiovascular, metabolic, infectious disease, oncology and urology.

Honggang Bi, corporate VP and general manager of China at Covance, said: “This agreement is the first of its kind signed with a partner in the Asia Pacific region, and Covance looks forward to collaborating with Sihuan Pharmaceutical in its efforts to potentially bring global filing strategies to realisation.” 

“With multiple compounds in its development pipeline, Sihuan Pharmaceutical is a promising pharmaceutical company to watch for groundbreaking new therapies.”

Specifically, Sihuan will be provided with drug development and regulatory expertise, particularly in efforts to achieve dual or multiple filings for regulatory approvals such as investigational new drug (IND) applications and new drug applications (NDA) in China and internationally.

Dr Frank Wu, chief scientific officer of Sihuan Pharmaceutical, commented: “The partnership is another milestone for our international collaboration and R&D team, which will enable us to accelerate the development of our pipeline, in turn helping to bring treatments to multiple markets faster, a key point of differentiation in the Chinese pharmaceutical industry.”

LabCorp announced the acquisition of full-service drug development firm Covance last November, with the deal being valued at $5.6bn.

Article by
Kirstie Pickering

2nd April 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics